Skip to content

Validation and Reproducibility of S.P.A.T. With Allergens

Validation and Reproducibility of Type I Hypersensitivity Reaction in the Diagnostic Process of the Skin Prick Test in Allergic and Non-allergic Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05824637
Enrollment
112
Registered
2023-04-21
Start date
2023-03-18
Completion date
2023-06-30
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy to House Dust, Allergy Pollen

Brief summary

To improve accuracy and take out human error opportunities, Hippo Dx developed S.P.A.T., an automated skin prick test. This study will provide a comparison between manual and automated skin prick test in allergic and non-allergic individuals with a panel of common inhalant allergens. The primary endpoint is to compare the accuracy of S.P.A.T. to detect sensitization to common aeroallergens compared to a manual skin prick test (SPT). It is a prospective monocentric study that will include 120 study participants.

Interventions

skin prick test to detection sensitisation to aeroallergens

DIAGNOSTIC_TESTSkin Prick Manual Test

skin prick test to detection sensitisation to aeroallergens

Sponsors

Hippocreates
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Adults (18-65y) with presence or absence of self-reported symptoms of inhalant allergy will be included.

Exclusion criteria

* Skin pathology like chronic or exuberant urticaria, dermographism, chronic dermatitis that needs daily treatment * Use of antihistaminic medication \< 7 days before the start of the study * Use of tricyclic antidepressants (antihistamine activity) \< 7 days before the start of the study * Use of topical corticoids on the forearm \< 7 days before the start of the study * Use of Omalizumab \< 6 months before the start of the study * Pregnancy: there is a remote possibility of inducing a systemic allergic reaction that could induce uterine contractions or necessitate the use of epinephrine (thought to cause constriction of the umbilical artery)

Design outcomes

Primary

MeasureTime frameDescription
Within-test agreement (% of patients with consistent results) of wheal positivity per allergen between manual and automated test.15 minutes after the diagnostic testEach of the allergens are pricked three times via manual and automated skin prick test. Three positive or negative test results are considered consistent whereas either one or two positive or negative test results are considered non-consistent resulting in an inconclusive test result.

Secondary

MeasureTime frameDescription
Allergy symptoms assessed by visual analogue scale between patients with a positive versus negative test result.day of the diagnostic testVisual analogue scale (0: best - 10: worse)
Time (seconds) required to run an automated versus a manual skin prick test.during the diagnostic test
Amount of allergen solution that is required to run an automated versus a manual skin prick test.during the diagnostic test
Level of discomfort experienced by the patient as assessed by visual analogue scale after an automated versus a manual skin prick test.15 minutes after the diagnostic testVisual analogue scale (0: best - 10: worse)

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026